CoreAge Rx: settle the charge and exit terms
Ask for a written quote before ordering. The CoreAge Rx review explains where the advertised prices and refund terms conflict, so you know which charges to confirm.
More on CoreAge Rx
In October 2026, CoreAge Rx’s product pages advertised semaglutide from $79 and tirzepatide from $129 a month. Navigation still promoted semaglutide from $99, and a separate campaign tied starting prices to twelve months paid in full. That annual condition does not establish the product-page offers’ terms. Confirm your selected bill and usable supply instead of comparing headline prices.
CoreAge’s FAQ said no automatic rebills and a full refund after clinical rejection. Its policy allowed subscriptions and retained any applicable $50–$100 consultation fee once review began, including after rejection. Cancellation must precede renewal processing to prevent the next charge; that does not refund an existing order.
Exit timing also needs clarification: the policy’s final-sale clause made prescriptions final after approval AND pharmacy transmission, while the Terms used completed review and/or transmission, subject to policy exceptions. A separate 30-calendar-day purchase cutoff applied even before shipment, except where law required otherwise. We would wait for the applicable terms in writing; our CoreAge review explains the conflicting disclosures.
On November 3, its policy also said that a clinician-advised stop for health concerns leaves eligible remaining prepaid value as store credit rather than cash. It allows transfer to another patient subject to medical approval, or use toward nonprescription products and future eligible services or products.